NEW YORK, March 19 – Toronto-based proteomics company Syn X Pharma said Monday it would build the infrastructure to conduct in-house clinical trials.

The company, which recently hired a proteomics executive from Ciphergen and a business development expert from Eli Lilly, said the move signaled its efforts to begin bringing its products to market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.